A Randomized, Double-blind, Two-arm, Parallel Group, Single-dose, Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors Celltrion
Most Recent Events
- 15 Sep 2023 New trial record